Return to search

QurAlis scores $42m Series A

Cambridge, Massachusetts-based QurAlis Corporation, a developer of precision therapeutics for amyotrophic lateral sclerosis and other neurologic diseases, has secured $42 million in Series A financing.

Cambridge, Massachusetts-based QurAlis Corporation, a developer of precision therapeutics for amyotrophic lateral sclerosis and other neurologic diseases, has secured $42 million in Series A financing. The lead backers were LS Polaris Innovation Fund, Mission BioCapital, INKEF Capital, the Dementia Discovery Fund and Droia Ventures.

Source: Press Release